BCRX (BioCryst Pharmaceuticals Inc)
Insider Trading Activity
Every open-market purchase and sale reported by BCRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Steven Frank | Director | A | — | — |
| 2026-09-02 | VINCENT MILANO | Director | A | — | — |
| 2026-09-02 | Jill C. Milne | Director | A | — | — |
| 2026-09-02 | Amy E McKee | Director | A | — | — |
| 2026-09-02 | Jon P Stonehouse | Director | A | — | — |
| 2026-06-15 | THERESA HEGGIE | Director | A | — | — |
| 2026-06-15 | VINCENT MILANO | Director | A | — | — |
| 2026-06-15 | Jill C. Milne | Director | A | — | — |
| 2026-06-15 | MACHELLE SANDERS | Director | A | — | — |
| 2026-06-15 | Steven K Galson | Director | A | — | — |
| 2026-06-15 | Jon P Stonehouse | Director | A | — | — |
| 2026-06-15 | Amy E McKee | Director | A | — | — |
| 2026-06-15 | Steven Frank | Director | A | — | — |
| 2026-06-15 | ALAN G LEVIN | Director | A | — | — |
| 2026-06-02 | Jon P Stonehouse | Director | A | — | — |
| 2026-06-02 | Steven Frank | Director | A | — | — |
| 2026-06-02 | VINCENT MILANO | Director | A | — | — |
| 2026-06-02 | Jill C. Milne | Director | A | — | — |
| 2026-06-02 | Amy E McKee | Director | A | — | — |
| 2026-05-19 | Amy E McKee | Director | Sell | — | — |
| 2026-05-15 | Alane P Barnes | Chief Legal Officer | MIXED | — | — |
| 2026-04-07 | Sandeep Menon | Chief R&D Officer | A | — | — |
| 2026-03-24 | THERESA HEGGIE | Director | MIXED | — | — |
| 2026-03-18 | Alane P Barnes | Chief Legal Officer | MIXED | — | — |
| 2026-03-03 | VINCENT MILANO | Director | A | — | — |
| 2026-03-03 | Jill C. Milne | Director | A | — | — |
| 2026-03-03 | Amy E McKee | Director | A | — | — |
| 2026-03-03 | Steven Frank | Director | A | — | — |
| 2026-03-03 | Jon P Stonehouse | Director | MIXED | — | — |
| 2026-01-27 | Jill C. Milne | Director | A | — | — |
| 2025-12-23 | Jon P Stonehouse | Chief Executive Officer | F | — | — |
| 2025-12-23 | Charles K Gayer | President and CCO | MIXED | — | — |
| 2025-12-23 | Alane P Barnes | Chief Legal Officer | MIXED | — | — |
| 2025-12-19 | Charles K Gayer | President and CCO | A | — | — |
| 2025-12-19 | Jon P Stonehouse | Chief Executive Officer | G | — | — |
| 2025-12-19 | Alane P Barnes | Chief Legal Officer | A | — | — |
| 2025-12-19 | Babar Ghias | Chief Financial Officer | A | — | — |
| 2025-12-16 | Alane P Barnes | Chief Legal Officer | MIXED | — | — |
| 2025-12-16 | Jon P Stonehouse | Chief Executive Officer | F | — | — |
| 2025-12-16 | Charles K Gayer | President and CCO | F | — | — |
| 2025-12-03 | Alane P Barnes | Chief Legal Officer | MIXED | — | — |
| 2025-12-02 | Steven Frank | Director | A | — | — |
| 2025-12-02 | VINCENT MILANO | Director | A | — | — |
| 2025-12-02 | Amy E McKee | Director | A | — | — |
| 2025-11-17 | MACHELLE SANDERS | Director | Sell | — | — |
| 2025-09-03 | Amy E McKee | Director | A | — | — |
| 2025-09-03 | VINCENT MILANO | Director | A | — | — |
| 2025-09-03 | Steven Frank | Director | A | — | — |
| 2025-08-15 | THERESA HEGGIE | Director | MIXED | — | — |
| 2025-07-28 | Babar Ghias | CFO & Head of Corp Development | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,090,786 | — |
| — | 10%+ Owner | 3,841,124 | — |
| — | 10%+ Owner | 2,145,586 | — |
| — | Director | 2,040,110 | — |
| — | 10%+ Owner | 1,680,147 | — |
| — | 10%+ Owner | 1,642,513 | — |
| — | Chief Executive Officer | 1,380,419 | — |
| — | President and CCO | 892,492 | — |
| — | Chief Legal Officer | 463,203 | — |
| — | Chief Financial Officer | 380,328 | — |
| — | Chief R&D Officer | 377,318 | — |
| — | Chief Discovery Officer | 330,056 | — |
| — | Chief Financial Officer | 268,700 | — |
| — | Chief R&D Officer | 205,150 | — |
| — | Director | 173,660 | — |
| — | 10%+ Owner | 128,783 | — |
| — | Senior Vice President and CFO | 125,176 | — |
| — | Director | 109,642 | — |
| — | Director | 100,198 | — |
| — | Director | 99,138 | — |
| — | Director | 86,165 | — |
| — | Director | 80,646 | — |
| — | Director | 79,565 | — |
| — | Chief Operating Officer | 77,293 | — |
| — | Director | 72,659 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BCRX quote page; the site-wide leaderboard is on the insider transactions hub.